EMP1 and neoplasm: Both in vivo and in vitro results from our study indicate that the oncogenic effects of EMP1 in PC can be reversed by PI3K/AKT pathway inhibitors, suggesting the potential for combinatorial therapeutic strategies targeting EMP1 and PI3K/AKT to treat PC, inhibit tumor metastasis, delay disease progression, and potentially improve patient prognosis.